Prolia Mechanism of Action*
Prolia is the first RANK ligand inhibitor that inhibits the activity of osteoclasts before they get to bone. Prolia’s mechanism of action inhibits the activity of osteoclasts before they get to bone; decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone throughout the skeleton.1*
Mechanism of Action in Postmenopausal Osteoporosis*
*Clinical significance has not been established.
† Comparative clinical significance has not been established.
Learn more about Amgen CanadaAmgen canada
|1.||Prolia Product Monograph. Amgen Canada Inc., March 29, 2022.|
|2.||Actonel®/Actonel DR® Product Monograph. Allergan Pharma Co., August 3, 2017.|